Laboratory of Carbohydrate Science and Engineering, Chongqing Normal University, Chongqing 401331, China.
Laboratory of Carbohydrate Science and Engineering, Chongqing Normal University, Chongqing 401331, China.
Biomed Pharmacother. 2022 Feb;146:112556. doi: 10.1016/j.biopha.2021.112556. Epub 2021 Dec 22.
Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. Recent studies have shown that butyrylcholinesterase (BuChE) inhibitors or double acetyl and butyryl cholinesterase inhibitors have better curative effects on AD, and the side effects are lower than those of specific AChE inhibitors. Dual target cholinesterase inhibitors have become a new hotspot in the research of anti-AD drugs. Herein, the synthesis and bioactivities of BuChE inhibitors were reviewed.
乙酰胆碱酯酶 (AChE) 抑制剂是治疗阿尔茨海默病 (AD) 的首选药物，但存在一些缺陷，如剂量限制和不理想的长期治疗效果。最近的研究表明，丁酰胆碱酯酶 (BuChE) 抑制剂或双乙酰和丁酰胆碱酯酶抑制剂对 AD 的治疗效果更好，副作用低于特定的 AChE 抑制剂。双靶胆碱酯酶抑制剂已成为抗 AD 药物研究的新热点。本文综述了 BuChE 抑制剂的合成及生物活性。
